Literature DB >> 32746876

Correction to: m6A mRNA methylation initiated by METTL3 directly promotes YAP translation and increases YAP activity by regulating the MALAT1-miR-1914-3p-YAP axis to induce NSCLC drug resistance and metastasis.

Dan Jin1, Jiwei Guo2, Yan Wu3, Jing Du3, Lijuan Yang3, Xiaohong Wang4, Weihua Di5, Baoguang Hu6, Jiajia An7, Lingqun Kong8, Lei Pan9, Guoming Su10.   

Abstract

An amendment to this paper has been published and can be accessed via the original article.

Entities:  

Year:  2020        PMID: 32746876      PMCID: PMC7397643          DOI: 10.1186/s13045-020-00942-x

Source DB:  PubMed          Journal:  J Hematol Oncol        ISSN: 1756-8722            Impact factor:   17.388


Correction to: J Hematol Oncol 12:135 (2019) https://doi.org/10.1186/s13045-019-0830-6 The original article [1] contains errors in Fig. 2h, Fig. 2n and Fig. 6k:
Fig. 2

YTHDF3 recognizes m6A modification and promotes cellular growth and migration via YAP upregulation. h The expressions of YAP and its target genes, CTGF and Cyr61, were analyzed by RT-PCR and western blot. n The cellular invasion and migration growths were analyzed by transwell assay. Results were presented as mean ± SD of three independent experiments. *P < 0.05 or **P < 0.01 indicates a significant difference between the indicated groups. NS, not significant

Fig. 6

The reduction of YAP m6A modification inhibits tumor growth and enhances DDP sensitivity in vivo. k The tumor nodules from controlvector, METTL3Vector and METTL3shYap groups were treated with PBS or DDP every three days. The protein expression levels of Ki67, ABCG2 and ERCC1were analyzed immunohistochemical staining assays (n = 5). Results were presented as mean ± SD three independent experiments. **P < 0.01 indicates a significant difference between the indicated groups. NS, not significant

In Fig. 2h, the protein band of YTHDF3 was mistakenly duplicated into the protein band of Cyr61. In Fig. 2n, the image of Control+Vector treatment group was mistakenly duplicated into the siMETTL3 + YTHDF3 treatment group, and the image of METTL3 + siYTHDF3 treatment group was unintentionally duplicated into the METTL3 + YTHDF3 treatment group which were determined by transwell assay. In Fig. 6k, the IHC image of ABCG2 was unintentionally duplicated onto the IHC image of ERCC1. YTHDF3 recognizes m6A modification and promotes cellular growth and migration via YAP upregulation. h The expressions of YAP and its target genes, CTGF and Cyr61, were analyzed by RT-PCR and western blot. n The cellular invasion and migration growths were analyzed by transwell assay. Results were presented as mean ± SD of three independent experiments. *P < 0.05 or **P < 0.01 indicates a significant difference between the indicated groups. NS, not significant The reduction of YAP m6A modification inhibits tumor growth and enhances DDP sensitivity in vivo. k The tumor nodules from controlvector, METTL3Vector and METTL3shYap groups were treated with PBS or DDP every three days. The protein expression levels of Ki67, ABCG2 and ERCC1were analyzed immunohistochemical staining assays (n = 5). Results were presented as mean ± SD three independent experiments. **P < 0.01 indicates a significant difference between the indicated groups. NS, not significant These errors were mistakenly introduced when organising the results; however, these errors have no bearing on the work’s scientific conclusions as the statistical results are based on the correct pictures. The authors would like to note the correct versions of each of the above-noted sub-figures ahead. The only changes are to the panels of Fig. 2h, Fig. 2n, and Fig. 6k, and the rest of the figures are identical to the published version; furthermore, no other errors were found after repeated checking of the published data. The authors apologise to the Editor of Journal of Hematology & Oncology and to the readership for any inconvenience caused.
  1 in total

1.  m6A mRNA methylation initiated by METTL3 directly promotes YAP translation and increases YAP activity by regulating the MALAT1-miR-1914-3p-YAP axis to induce NSCLC drug resistance and metastasis.

Authors:  Dan Jin; Jiwei Guo; Yan Wu; Jing Du; Lijuan Yang; Xiaohong Wang; Weihua Di; Baoguang Hu; Jiajia An; Lingqun Kong; Lei Pan; Guoming Su
Journal:  J Hematol Oncol       Date:  2019-12-09       Impact factor: 17.388

  1 in total
  3 in total

1.  Bioinformatics Analysis of the Characteristics and Correlation of m6A Methylation in Breast Cancer Progression.

Authors:  Ping Zhao; Xinwei Huang; Anhao Wu; Xin Yang; Yang Fu; Yuhang Quan; Ji Zhang; Zhen Li; Qi Tang; Maohua Wang
Journal:  Contrast Media Mol Imaging       Date:  2022-05-21       Impact factor: 3.009

2.  Characterization of m6A RNA Methylation Regulators Predicts Survival and Immunotherapy in Lung Adenocarcinoma.

Authors:  Minggao Zhu; Yachao Cui; Qi Mo; Junwei Zhang; Ting Zhao; Yujie Xu; Zhenpeng Wu; Donglin Sun; Xiaoren Zhang; Yingchang Li; Qiang You
Journal:  Front Immunol       Date:  2021-12-17       Impact factor: 7.561

Review 3.  The interplay between m6A modification and non-coding RNA in cancer stemness modulation: mechanisms, signaling pathways, and clinical implications.

Authors:  Sha Qin; Yitao Mao; Haofan Wang; Yingxing Duan; Luqing Zhao
Journal:  Int J Biol Sci       Date:  2021-06-26       Impact factor: 6.580

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.